TY - JOUR
T1 - Mometasone Furoate in Non-Allergic Rhinitis: A Real-Life Italian Study
AU - Rizzi, Angela
AU - Parrinello, Giuseppe
AU - De Corso, Eugenio
AU - Tricarico, Laura
AU - Centrone, Michele
AU - Di Rienzo, Alessia
AU - Laface, Chiara
AU - Passali, Giulio Cesare
AU - Cadoni, Gabriella
AU - Inchingolo, Riccardo
AU - Paludetti, Gaetano
AU - Galli, Jacopo
AU - Nucera, Eleonora
PY - 2022
Y1 - 2022
N2 - Background: In order to evaluate the efficacy of intranasal mometasone furoate in patients with non-allergic rhinitis (NAR), a real-life, observational, prospective study is performed. Methods: Thirty-one patients (age 18-64 years) receive intranasal (mometasone furoate, 200 mu g b.i.d. for 15 consecutive days per month for 6 consecutive months), plus isotonic nasal saline. The cytologic pattern of local inflammation, nasal airflow, through peak nasal inspiratory flow (PNIF), quality of life (QoL), through the rhinitis quality of life questionnaire (RQLQ), the sinonasal outcome test (SNOT-22), the short-form 36-item health survey (SF-36v2), and the combined symptom medication score (CSMS), and, finally, olfactory function, through Sniffin' sticks-16 identification test (SSIT-16), are evaluated at baseline and after treatment. Results: NARNE is the most frequent cytological pattern (48% of the total sample). The therapeutic response shows improvement in olfactory function and QoL. Conclusions: The results of this study confirm that intranasal mometasone furoate is an effective treatment for patients with NAR.
AB - Background: In order to evaluate the efficacy of intranasal mometasone furoate in patients with non-allergic rhinitis (NAR), a real-life, observational, prospective study is performed. Methods: Thirty-one patients (age 18-64 years) receive intranasal (mometasone furoate, 200 mu g b.i.d. for 15 consecutive days per month for 6 consecutive months), plus isotonic nasal saline. The cytologic pattern of local inflammation, nasal airflow, through peak nasal inspiratory flow (PNIF), quality of life (QoL), through the rhinitis quality of life questionnaire (RQLQ), the sinonasal outcome test (SNOT-22), the short-form 36-item health survey (SF-36v2), and the combined symptom medication score (CSMS), and, finally, olfactory function, through Sniffin' sticks-16 identification test (SSIT-16), are evaluated at baseline and after treatment. Results: NARNE is the most frequent cytological pattern (48% of the total sample). The therapeutic response shows improvement in olfactory function and QoL. Conclusions: The results of this study confirm that intranasal mometasone furoate is an effective treatment for patients with NAR.
KW - fiberoptic nasal endoscopy
KW - intranasal corticosteroid
KW - mometasone furoate
KW - nasal cytology
KW - non-allergic rhinitis
KW - non-allergic rhinitis with eosinophils (NARES)
KW - olfactory function
KW - quality of life
KW - the rhinitis quality of life questionnaire (RQLQ)
KW - fiberoptic nasal endoscopy
KW - intranasal corticosteroid
KW - mometasone furoate
KW - nasal cytology
KW - non-allergic rhinitis
KW - non-allergic rhinitis with eosinophils (NARES)
KW - olfactory function
KW - quality of life
KW - the rhinitis quality of life questionnaire (RQLQ)
UR - http://hdl.handle.net/10807/214846
U2 - 10.3390/jpm12071179
DO - 10.3390/jpm12071179
M3 - Article
SN - 2075-4426
VL - 12
SP - 1179
EP - 1181
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
ER -